×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INMB – inmune bio inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INMB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/10
08:00 am
inmb
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
Low
Report
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
12/4
03:07 pm
inmb
OmniScience and INmune Bio Partner for Alzheimer's Trial [Yahoo! Finance]
Low
Report
OmniScience and INmune Bio Partner for Alzheimer's Trial [Yahoo! Finance]
12/4
09:12 am
inmb
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower [Yahoo! Finance]
Medium
Report
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower [Yahoo! Finance]
12/4
09:00 am
inmb
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
Medium
Report
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
12/4
09:00 am
inmb
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
Medium
Report
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
11/13
09:00 am
inmb
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
Low
Report
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
11/3
08:39 am
inmb
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) [Yahoo! Finance]
Low
Report
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) [Yahoo! Finance]
10/31
04:05 pm
inmb
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
Medium
Report
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
Date
Time
Symbol
Company Name
Action
%Chg
10/31/2024
04:05 pm
inmb
inmune bio inc. - common stock
MISS
Report
3.2%
inmune bio inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/9
04:01 pm
inmb
Form 4 Inmune Bio, Inc. For: Dec 05 Filed by: Lowdell Mark William
Low
Report
Form 4 Inmune Bio, Inc. For: Dec 05 Filed by: Lowdell Mark William
12/9
04:01 pm
inmb
Form 4 Inmune Bio, Inc. For: Dec 05 Filed by: Tesi Raymond Joseph
Low
Report
Form 4 Inmune Bio, Inc. For: Dec 05 Filed by: Tesi Raymond Joseph
12/9
04:01 pm
inmb
Form 4 Inmune Bio, Inc. For: Dec 05 Filed by: ALLEN MARCIA
Low
Report
Form 4 Inmune Bio, Inc. For: Dec 05 Filed by: ALLEN MARCIA
12/9
04:01 pm
inmb
Form 8-K Inmune Bio, Inc. For: Dec 04
Low
Report
Form 8-K Inmune Bio, Inc. For: Dec 04
12/9
04:01 pm
inmb
Form 4 Inmune Bio, Inc. For: Dec 05 Filed by: Ganjei James Kelly
Low
Report
Form 4 Inmune Bio, Inc. For: Dec 05 Filed by: Ganjei James Kelly
12/9
04:01 pm
inmb
Form 4 Inmune Bio, Inc. For: Dec 05 Filed by: Schroeder Timothy j
Low
Report
Form 4 Inmune Bio, Inc. For: Dec 05 Filed by: Schroeder Timothy j
12/9
04:01 pm
inmb
Form 4 Inmune Bio, Inc. For: Dec 05 Filed by: Juda Scott
Low
Report
Form 4 Inmune Bio, Inc. For: Dec 05 Filed by: Juda Scott
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/11
Form 10-K Inmune Bio, Inc. For: Dec 31
26.3%
4/24 Form 424B3 Inmune Bio, Inc. 20.9%
10/21 Form 8-K Inmune Bio, Inc. For: Oct 16 13.8%
10/17 INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting 12.2%
12/17 INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials 11.8%
9/4 INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference 10.9%
8/21 Form 4 Inmune Bio, Inc. For: Aug 20 Filed by: Tesi Raymond Joseph 9.1%
4/20 INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19 7.7%
9/4 Form 8-K Inmune Bio, Inc. For: Sep 04 7.7%
8/16 Form 3 Inmune Bio, Inc. For: Aug 06 Filed by: Baracchini Edgardo Jr 7.5%
4/24 Form 424B3 Inmune Bio, Inc. 20.9%
10/21 Form 8-K Inmune Bio, Inc. For: Oct 16 13.8%
10/17 INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting 12.2%
12/17 INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials 11.8%
9/4 INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference 10.9%
8/21 Form 4 Inmune Bio, Inc. For: Aug 20 Filed by: Tesi Raymond Joseph 9.1%
4/20 INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19 7.7%
9/4 Form 8-K Inmune Bio, Inc. For: Sep 04 7.7%
8/16 Form 3 Inmune Bio, Inc. For: Aug 06 Filed by: Baracchini Edgardo Jr 7.5%
TOP News Decliners
3/11
INmune Bio Inc. (INMB) CEO R.J. Tesi on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
-29.8%
10/8 Form 8-K Inmune Bio, Inc. For: Oct 08 -13.2%
5/17 INmune Bio Inc (NASDAQ: INMB) was given a new $13.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -12.3%
8/7 Form 8-K Inmune Bio, Inc. For: Aug 05 -12.2%
8/15 Form 8-K Inmune Bio, Inc. For: Aug 14 -9.8%
4/21 Form EFFECT Inmune Bio, Inc. -9.7%
4/3 Form EFFECT Inmune Bio, Inc. -8.3%
8/21 INmune Bio Inc (NASDAQ: INMB) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -8.2%
3/12 Form 8-K Inmune Bio, Inc. For: Mar 11 -8.0%
8/9 Form 8-K Inmune Bio, Inc. For: Aug 05 -7.8%
10/8 Form 8-K Inmune Bio, Inc. For: Oct 08 -13.2%
5/17 INmune Bio Inc (NASDAQ: INMB) was given a new $13.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -12.3%
8/7 Form 8-K Inmune Bio, Inc. For: Aug 05 -12.2%
8/15 Form 8-K Inmune Bio, Inc. For: Aug 14 -9.8%
4/21 Form EFFECT Inmune Bio, Inc. -9.7%
4/3 Form EFFECT Inmune Bio, Inc. -8.3%
8/21 INmune Bio Inc (NASDAQ: INMB) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -8.2%
3/12 Form 8-K Inmune Bio, Inc. For: Mar 11 -8.0%
8/9 Form 8-K Inmune Bio, Inc. For: Aug 05 -7.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: